Navigation Links
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Date:3/20/2012

includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, autism, anxiety & depression, chronic insomnia, addiction and diabetes.  For more information, please visit http://www.heptares.com.

References

  1. Langmead, C. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201455y. Published online: January 17, 2012
  2. Congreve, M. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201376w. Published online: January 5, 2012
  3. Zhukov, A. et al. (2012) J. Med. Chem., 2011, 54 (13), pp 4312-4323

Contact Information

Citigate DeweRogerson (for Heptares)
Mark Swallow, Chris Gardner
+1 857-222-4586
dan.grau@heptares.com

+44 (0)20-7282-2948
mark.swallow@citigatedr.co.uk

Heptares Therapeutics Ltd

Malcolm Weir, Chief Executive Officer (UK)
+44 (0)1707-358-629
malcolm.weir@heptares.com

Dan Grau, President (USA)
+1-857-222-4586
dan.grau@heptares.com



'/>"/>
SOURCE Heptares Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
2. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
3. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
4. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
7. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
8. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
9. Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock
10. FDA Grants Fast Track Designation to Tioga Pharmaceuticals Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
11. FDA Grants Fast Track Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... , July 24, 2014 Lyfebulb, ... Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North ... or "the Company"), announced a collaboration to increase ... last night at an event attended by more ... parties. Lyfebulb is a health and wellness company ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... Each year, thousands of Amgen staff generously devote their ... charitable organizations. To recognize these exceptional efforts, the Amgen Foundation ... Excellence in Volunteering Awards. The Awards ... Rico who are making a difference in the communities ...
... 2011 Generex Biotechnology Corporation ( www.generex.com ) ... status of the previously announced spinout of its ... The Company is in the midst ... transaction opportunities, including both shell companies and operating ...
... 2011 EvaluatePharma Ltd, the research company, is ...  With a team based in Tokyo, EvaluatePharma Japan KK will ... Japan. "Japan is a very important market for ... major customers from a distance, but it is now time ...
Cached Biology Technology:Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits 2Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits 3Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4EvaluatePharma Japan KK - Now Open for Business in Tokyo 2
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... , This release is available in German ... now be produced inexpensively and in large quantities. This means ... 225 million malaria patients in developing countries at an affordable ... Interfaces in Potsdam and the Freie Universitt Berlin have developed ...
... Can a one-size-fits all approach really work? The world ... In the west it is already widespread and it ... change in the lifestyles of recent generations., "Fat, Fate and ... tackled by focusing solely on adult lifestyles and asks the ...
... evolve the ability to grow beyond the tissues in ... tumor cells -- are tethered to scaffolding that helps ... University of Helsinki, Finland, and from UCSF have identified ... them to further misbehave. The protein, they ...
Cached Biology News:Anti-malaria drug synthesized with the help of oxygen and light 2Anti-malaria drug synthesized with the help of oxygen and light 3'Fat, Fate and Disease' 2Some breast cancer spread may be triggered by a protein, study shows 2Some breast cancer spread may be triggered by a protein, study shows 3
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Black 96 Well Plate EB, RE Bottom...
...
...
Biology Products: